Standalone Audited Financial Result for the quarter and year ended on 31.03.2026

Revenue Growth 20pctEmphasis Of MatterRelated Party TransactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹5.71

prior close

₹5.91

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+1.5% vs market

Pharmaceuticals peers, median of 162sector-0.5%+1.4% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-0.8

15m

-1.0

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9-0.6+1.5-0.5+1.4

Next day

+3.2-1.7+4.9-1.2+4.4

+1.8-0.7+2.4-1.5+3.2

+3.3-0.4+3.7-1.6+5.0

+10.7+0.4+10.2-1.1+11.8

+17.7+0.4+17.3-1.3+19.0

+17.0+0.3+16.7-1.0+17.9

15d

+49.2+5.5+43.7+0.7+48.5

+32.6+4.6+28.0+2.3+30.2

+21.2+5.3+15.9+5.1+16.1

+21.4+11.6+9.8+6.8+14.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Achyut Healthcare reported revenue from operations of ₹1,159.47 Lakhs for FY26, a massive jump of 280% compared to ₹304.75 Lakhs in FY25. However, net profit declined to ₹31.57 Lakhs from ₹51.47 Lakhs in the previous year (a 39% drop). The company transitioned to Indian Accounting Standards (Ind AS) for the first time this year after migrating from SME to Main Board of BSE in January 2026. Q4 standalone revenue was ₹438.64 Lakhs. The auditor issued an unmodified opinion with an Emphasis of Matter paragraph noting the Ind AS transition. The company also reported related party transactions for the half year ended March 2026.

Likely market impact

While revenue surged significantly driven by increased pharmaceutical business activity, the decline in profit margins and lower PAT compared to last year may concern investors. The Ind AS transition and the auditors' unmodified opinion indicate no material concerns about financial reporting quality.